|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$104,000
|
N/A
|
National Institutes of Health
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$1,803,769
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cancer Center Support Grant
|
5P30CA008748-51
|
$12,352,942
|
$123,529
|
THOMPSON, CRAIG
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Dana-Farber/Harvard Cancer Center
|
2P30CA006516-52
|
$11,592,798
|
$115,928
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-41
|
$7,810,244
|
$468,615
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Cancer Center Support Grant
|
3P30CA082103-18S9
|
$6,765,398
|
$67,654
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
5P30CA014089-42
|
$6,263,488
|
$939,523
|
Wayne, Alan
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Cancer Center Support Grant Year 35 (CCSG)
|
5P30CA021765-38
|
$6,063,271
|
$60,633
|
ROBERTS, CHARLES
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Specialized Cancer Center Support Grant
|
5P30CA023100-31
|
$3,795,641
|
$37,956
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Childhood Cancer Survivor Study
|
2U24CA055727-23
|
$3,616,741
|
$361,674
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,583,320
|
$179,166
|
Glod, John
|
CCR (NCI)
|
|
Stanford Cancer Institute
|
5P30CA124435-10
|
$3,338,488
|
$33,385
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
$130,125
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
$26,456
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
|
1P01CA217959-01
|
$2,296,936
|
$2,296,936
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
5P30CA051008-24
|
$2,258,441
|
$22,584
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
2P30CA016059-36
|
$2,164,167
|
$108,208
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Fred & Pamela Buffett Cancer Center Support Grant
|
5P30CA036727-31
|
$2,107,000
|
$42,140
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
ENHANCING T CELL THERAPY OF CANCER
|
5P01CA094237-15
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$111,482
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523
|
2R42CA192656-02A1
|
$1,320,558
|
$1,320,558
|
DURDEN, DONALD
|
SIGNALRX PHARMACEUTICALS, INC.
|
|
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers
|
1U01CA217864-01
|
$1,065,613
|
$532,807
|
WEISS, WILLIAM
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Development of new antibody-based cancer therapies
|
ZIA BC 010891
|
$942,291
|
$942,291
|
Ho, Mitchell
|
CCR (NCI)
|
|
HiTIF Microscopy Core Facility
|
ZIC BC 011567
|
$858,349
|
$171,670
|
Pegoraro, Gianluca
|
CCR (NCI)
|
|
Targeting Neuroblastoma with armed T cells
|
5R01CA182526-04
|
$765,563
|
$765,563
|
LUM, LAWRENCE
|
UNIVERSITY OF VIRGINIA
|
|
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes
|
1R35CA220500-01
|
$683,163
|
$683,163
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Regulation of Differentiation of Pediatric Embryonal Tumors- Neuroblastoma
|
ZIA BC 010788
|
$665,693
|
$499,270
|
Thiele, Carol
|
CCR (NCI)
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-26
|
$635,460
|
$317,730
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-10
|
$614,290
|
$614,290
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
5R01CA180692-03
|
$606,838
|
$606,838
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of Neurotrophins in the Development of the Mammalian Nervous System
|
ZIA BC 010390
|
$525,343
|
$105,069
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of Trk Receptors in the Development and Function of Non-neuronal Structures
|
ZIA BC 010391
|
$512,529
|
$51,253
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Identification of Novel Mutations In Pediatric Cancers
|
ZIA BC 010998
|
$511,155
|
$204,462
|
Khan, Javed
|
CCR (NCI)
|
|
Clinical Development of Novel Drugs for Children with Refractory Cancers
|
ZIA SC 010354
|
$479,687
|
$23,984
|
Widemann, Brigitte
|
CCR (NCI)
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
$47,481
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Biomarkers and Therapeutic Targets in Angiogenesis and Metastasis
|
ZIA BC 011334
|
$474,811
|
$47,481
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Discovery of New Differentiation Agents for Neuroblastoma Therapy
|
1R15CA213199-01A1
|
$461,575
|
$461,575
|
DU, LIQIN
|
TEXAS STATE UNIVERSITY
|
|
Exosomes in tumor cell-mesenchymal stromal cell interaction
|
1R01CA207983-01A1
|
$423,016
|
$296,111
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
2R01CA148688-06A1
|
$413,844
|
$413,844
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
5R01CA197336-02
|
$407,748
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-04
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
A First-in-Human Pilot Study of 18F-MFBG Imaging for Evaluation of Neuroblastoma
|
1R01CA204093-01A1
|
$392,078
|
$392,078
|
PANDIT-TASKAR, NEETA
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Role of microRNAs released by Tumor Associated Macrophages within Exosomes in the chemoresistance of Neuroblastoma
|
1R01CA215753-01A1
|
$391,698
|
$391,698
|
FABBRI, MULLER
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Structural Variation in Neuroblastoma
|
5R01CA204974-02
|
$384,300
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Molecular Characteristics of Treatment-resistant High-risk Neuroblastoma
|
5R01CA197903-02
|
$378,357
|
$378,357
|
ZHONG, JOHN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-09
|
$374,324
|
$374,324
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
ABT-199 based therapies to treat neuroblastoma
|
1R01CA215610-01
|
$371,856
|
$371,856
|
FABER, ANTHONY
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-03
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
5R01CA172067-06
|
$363,425
|
$363,425
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
|
ZIA BC 010789
|
$358,450
|
$322,605
|
Thiele, Carol
|
CCR (NCI)
|
Total relevant funding to Neuroblastoma for this search: $23,594,430
|